Nature Reviews Cancer

Article	Citations
Computing brain metastasis impact	762
Fructose takes a detour to feed cancer	538
Combining spatial transcriptomics and AI to enhance brain tumour diagnosis	521
INVADEseq to study the intratumoural microbiota at host single-cell resolution	505
Exploiting metabolic cell death for cancer therapy	472
Implementing practice-changing progress for managing cancer of unknown primary	429
Oncofetal reprogramming in tumour development and progression	429
Combinatorial strategies to target RAS-driven cancers	395
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment	356
Emerging strategies to investigate the biology of early cancer	328
Claudin proteins as emerging therapeutic targets for solid tumours	320
Mapping the prostate cell family tree	317
Fighting cancer with fat	305
3D chromatin architecture as a predictor of somatic mutations in cancer genomes	286
Reply to ‘Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies’	286
Connie J. Eaves (1944–2024)	285
Avoiding cancer through collective behaviour	283
How medical anthropology can contribute to cancer research	271
Author Correction: Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma	266
The recruitment of metastasis-associated monocytes	264
The evolution of cancer and ageing: a history of constraint	263
Tertiary lymphoid structures as hubs of antitumour immunity	253
Translating premalignant biology to accelerate non-small-cell lung cancer interception	250
Epithelial and stromal co-evolution and complicity in pancreatic cancer	233
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies	232

Beyond genetics: driving cancer with the tumour microenvironment behind the wheel	230
Nanoreceptors take down mutant p53	225
Impersonating neurons	218
Tumour EVPs disrupt liver function	213
Defining a ‘cells to society’ research framework for appendiceal tumours	205
AACR 2025	203
Measuring HLA disruption using MHC Hammer	200
No mutation, tumour initiation	198
Persistence is key	190
Thelpers? More like Ttroublemakers	189
Gut microbes produce novel genotoxic metabolites	181
Dendritic cells rise and shine	179
Removing barriers to address sex differences in anticancer drug toxicity	177
3D bioprinted cancer models: from basic biology to drug development	174
Moonlighting functions of glucose metabolic enzymes and metabolites in cancer	172
Rethinking ovarian cancer III: the past decade and future directions	169
How chemokines organize the tumour microenvironment	167
Bone voyage: immune crosstalk sets sail	164
B-ring sterols to the rescue	161
Visualizing intratumoural heterogeneity with EpicMIBI	148
Double trouble for the tumour glycocode	145
Identifying spatial cellular structures with SPACE-GM	140
In-depth organoid profiling of pancreatic cancer	134
Linking cell mechanical memory and cancer metastasis	132
Beyond oncogenesis: the unexplored benefits of viruses in cancer immunity	132
Context-dependent synthetic lethality — an emerging precision therapeutic approach	131
Imaging the hallmarks of cancer	125
Environmental endocrine disruptors: rethinking the origins of early-onset ER+ breast cancer	118
Enhancer and metabolic rewiring by KMT2C–COMPASS or KMT2D–COMPASS family loss in cancer creates druggable vulnerabilities	112
The path to leptomeningeal metastasis	110
Metabolic interplays between the tumour and the host shape the tumour macroenvironment	109
Opportunities and challenges of targeting cGAS–STING in cancer	103
The immune microenvironment of colorectal cancer	102
Regulatory T cells in the tumour microenvironment	101
Dynamics and specificities of T cells in cancer immunotherapy	100
Leveraging the replication stress response to optimize cancer therapy	100
Understanding and addressing race disparities in childhood cancer outcomes	99
Encoding spatial tumour dynamics with Starfysh	94
Race influences the tumour microbiome	90
Deciphering the cancer genome and epigenome	90
ER stress sparks nerve pain	89
Being in the zone	86
Re-routing IgE for cancer therapy	86
Polygenic scores in cancer	85
Beat it!	83
Advancing AI for multi-omics and clinical data integration in basic and translational cancer research	82
Stem cells as an essential mediator of the exercise–tumorigenesis link	80
Detection of cytokine-responsive cells using CyCLoPs	79
RNA splicing dysregulation and the hallmarks of cancer	78
Acetyl-CoA metabolism in cancer	77

Targeted protein degradation for cancer therapy	76
Cancer nanomedicine	75
Local CAR manufacturing	74
Expanding the utility of precision oncology knowledge bases	74
NOTUM-mediated stem cell competition in CRC	74
Tamoxifen takes the wheel	72
When the time is right	71
Right ON target: a new RAS-GTP inhibitor	71
Chromothripsis in cancer	69
Decoding cancer across scales with metabolomics	66
Defining precancer: a grand challenge for the cancer community	63
GABA takes the edge off anti-tumour immunity	63
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities	62
Prime editing GEMMs to model cancer mutations	59
Integrative medicine in oncology: redefining the standard of care	58
Tertiary lymphoid structures in anticancer immunity	56
In vivo labelling system to study cell neighbourhoods	53
Revealing genomic secrets of archival FFPE samples	50
Judith Campisi (1948–2024)	50
New pathogen on the block	49
Melanomagenesis antagonizes stem cell ageing	48
Cancer risk in children with congenital anomalies	48
Inferring cancer metabolism from gene-expression data	45
Regulation of immune checkpoint molecules in cancer immune evasion and therapy	44
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart	43
N6-Methyladenosine: an RNA modification as a central regulator of cancer	43
Recent advances in therapeutic cancer vaccines	43
The present and future of the Cancer Dependency Map	42
Carcinogenesis at single-cell resolution	41
Focusing on the complex and dynamic interplay between ageing and cancer	41
Global post-mortem tissue donation programmes to accelerate cancer research	41
Patient-derived organoids unveil sarcoma vulnerabilities	41
Transfer RNAs as dynamic and critical regulators of cancer progression	40
A timeline of tumour-associated macrophage biology	38
Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy	38
Epigenomic heterogeneity as a source of tumour evolution	38
Traject3d for studying 3D cellular heterogeneity	36
Guardrails for the use of generalist AI in cancer care	35
Digitally enhanced Raman spectroscopy	35
Author Correction: Integrative medicine in oncology: redefining the standard of care	35
Harnessing the influenza virus to fight cancer	32
We cannot ignore the cancer risks of wildfires	31
Escaping the trap	30
AACR 2026	30
Targeting cancer cell dormancy	30
Mechanisms, challenges and opportunities for FLASH radiotherapy in cancer	29
Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity	29
Fcγ receptors and immunomodulatory antibodies in cancer	28
Neuro-immune cross-talk in cancer	28
Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity	27
mRNA-based cancer therapeutics	26
AACR 2024	25
Male melanoma comes of age	24
EMT in chemoresistance	24
The role of eIF4F-driven mRNA translation in regulating the tumour microenvironment	23
Fungi in cancer: not such a ‘fun-guy’	23
Next-generation epidemiologic cohorts for cancer aetiology	22
CAFs promote CRPC	21
Modelling and deciphering tumour metabolism in CRISPR screens	21
Mechanisms driving the immunoregulatory function of cancer cells	20
Advances in cutaneous squamous cell carcinoma	20
Decoding the functional impact of the cancer genome through protein–protein interactions	20
Key role for microbiota in gut–bone crosstalk	19
Decoding the basis of histological variation in human cancer	19
Energizing leukaemia	19
l-Fucose: a dietary sugar with multifaceted potential in the biology and therapy of cancer	17
Therapeutic resistance to anti-oestrogen therapy in breast cancer	17
Artificial intelligence-generated synthetic data for cancer research and clinical trials	17
Author Correction: Learning to distinguish progressive and non-progressive ductal carcinoma in situ	17
Advances in translational research of the rare cancer type adrenocortical carcinoma	17
Same same but different	17
Deep tissue imaging of cancer in the infrared	16
Inherited resilience	15
Inflammatory neutrophils	14
Multiomics-guided cellular immunotherapies	14
Stemness in solid malignancies: coping with immune attack	13
Message in a vesicle: T cells boost tumour immunity	13
Enhanced transposable elements	12
Too much of a good thing	12
Black voices in cancer research and oncology	12

Overcoming heterogeneity with 3D whole-tumour sampling	12
A fatty competitor in tumour immunity	11
Addressing the gaps in cancer screening for LGBTQ+ individuals	11
Androgen receptor activation for breast cancer therapy	11
Limiting bias in AI models for improved and equitable cancer care	11
Mapping out mitochondria	10
Air pollution promotes tumorigenesis through pre-existing oncogenic mutations	10
Glioblastomas remodel neural circuits	10
Targeting sex steroid biosynthesis for breast and prostate cancer therapy	9
Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection	9
Big data in basic and translational cancer research	9
Fungi in cancer	9
Pathogenesis of cancers derived from thyroid follicular cells	9
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment	9
Nucleotide metabolism: a pan-cancer metabolic dependency	9
Intercepting gastric cancer	8
Microbiota and immune-related adverse events in cancer immunotherapy	8
Proximity labelling to study chromatin interactomes	8
Modelling the ageing dependence of cancer evolutionary trajectories	8
Feeding latent brain metastasis	8
Functional m6A site detection by FOCAS	8
Breast milk for breast cancer detection	8
Tumour avatars to model patients’ responses to immunotherapy	7
The fibroinflammatory response in cancer	7
A viral coding circRNA contributes to HPV-driven oncogenesis	7
Conventional chemotherapy: millions of cures, unresolved therapeutic index	7
Obesity as a promoter in BRCA mutation carriers	6
VIBRANT: mapping cell phenotypes using vibrational spectroscopy	6
Understanding tumour endothelial cell heterogeneity and function from single-cell omics	6
Epigenetic memory	6
Defining and using immune archetypes to classify and treat cancer	6
Small speckles, big impact	6
Tracing the evolutionary history of breast cancer	5
A machine learning toolkit for subtyping cancer in existing and new datasets	5
Protection against tumour formation	5
Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications	5
Multiplex protein imaging in tumour biology	5
Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma	5
Targeting the roots of myeloid malignancies with T cell receptors	5
Replication timings affect the frequency of chromosomal translocation	5
PDX models for functional precision oncology and discovery science	4
scAtlasVAE: a deep learning framework for generating a human CD8+ T cell atlas	4
Lymphatic vessels in the age of cancer immunotherapy	4
Sex affects cancer genomes	4
Ageing lipids map melanoma’s journey	4
Exploiting temporal aspects of cancer immunotherapy	4
Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance	4
Lactate gives a sour taste	4
The dynamic role of platelets in cancer progression and their therapeutic implications	4
Heard immunity in CAR T cells	4
How protons pave the way to aggressive cancers	3
Epigenetic lesions drive gliomagenesis	3
Taking a detour	3
Advancing cancer research via comparative oncology	3
Mastering the use of cellular barcoding to explore cancer heterogeneity	3
Pressing defence	3
The rise of spatial insights into tumour tissue architecture	3
Striking the right balance with type I interferon signalling in cancer	3
Author Correction: The importance of 3D fibre architecture in cancer and implications for biomaterial model design	3
Rusting away with age	3
Hidden epithelial subtypes refine colorectal cancer classification	3
Aggregating premalignancy	3
Targeting the tumour’s little helpers	3
Managing cancer following the World Trade Center disaster	3
Salmonella, the insidious contributor to gallbladder and colon cancers	3
Shared immunosuppressive mechanism between pregnancy and cancer	3
Targeting aberrant splicing	3
Stromal cells drive tumorigenesis in BRCA1 mutation carriers	3
Phosphoinositide kinases in cancer: from molecular mechanisms to therapeutic opportunities	3
Oncologists must act to manage cancer detected through prenatal screening	3
Allies in the epidermis	3
Preprints as tools to advance careers	3
Liquid biopsies for Hodgkin lymphoma	3
Identification, functional insights and therapeutic targeting of EMT tumour states	3
Unravelling the genetics and epigenetics of the ageing tumour microenvironment in cancer	2
Circular RNA in cancer	2
Unlocking the potential of urine-based liquid biopsy through improved reporting and standardization	2
Serving sulfur to boost anti-tumour immunity	2
Approaching cancer during pregnancy	2
Investigating immune cells across time in vivo	2
Cancers make their own luck: theories of cancer origins	2
Eph receptors and ephrins in cancer progression	2
Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment	2
Revisiting the TGFβ paradox: insights from HPV-driven cancer and the DNA damage response	2
Cancer burden in low-income and middle-income countries	2
Stromal senescence contributes to age-related increases in cancer	2
A guide to transcriptomic deconvolution in cancer	2
Programming immune escape	2
Gender and sex interactions are intrinsic components of cancer phenotypes	2
Tracking genome evolution following p53 inactivation	2
Translating p53-based therapies for cancer into the clinic	2
Mesenchymal stromal/stem cells in tumour initiation, progression and therapy	2
Unlocking the potential of FinnGen to advance cancer research	2
Characterization of the B cell receptor repertoire in melanoma	2
Why do patients with cancer die?	2